Xeros ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
53シェーグレン症候群16

53. シェーグレン症候群


臨床試験数 : 283 薬物数 : 320 - (DrugBank : 101) / 標的遺伝子数 : 56 - 標的パスウェイ数 : 181
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04252209
(ClinicalTrials.gov)
August 202126/1/2020the Effect of Mixture of Natural Products As Salivary Substitutes in Treatment Of Xerostomiathe Effect of Mixture of Natural Products As Salivary Substitute In Comparison To Carboxy Methyl Cellulose In Treatment Of Xerostomia In Patients With Sjogren's Syndrome: Cross Over Randomized Clinical TrialSjogren's Syndrome;XerostomiaOther: natural herbs of coconut, aloe vera, and pepperint;Other: carboxy methyl celluloseCairo UniversityNULLNot yet recruiting18 Years80 YearsAll44Phase 3NULL
2NCT01759108
(ClinicalTrials.gov)
March 13, 202023/12/2012Rebamipide AND Sjögren SyndromeRebamipide for the Treatment of Xerostomia in Sjögren SyndromeImproving Symptoms of Dry Mouth in Sjogren's SyndromeDrug: RebamipideUniversity of AlexandriaNULLRecruitingN/AN/AAll55N/AEgypt
3JPRN-UMIN000010710
2013/05/1515/05/2013Effective treatment of rebamipide on xerostomia in Sjogrens syndrome patients:a pilot study -a double-blind placebo-controlled trial- Xerostomia in Sjogrens syndromeRebamipide was administered orally at 100 mg each time three times a day after meals for 8 weeks.
Placebo was administered orally three times a day after meals for 8 weeks.
Tochigi medical centerNULLComplete: follow-up complete20years-old80years-oldMale and Female60Phase 2Japan
4NCT03578900
(ClinicalTrials.gov)
January 1, 201318/5/2018Quality of Life and Sjögren SyndromeQuality of Life in a Portuguese Population With Primary Sjögren SyndromeXerostomia;Hyposalivation;Quality of Life;Sjogren's SyndromeDrug: Xeros;Drug: Citric Acid based MouthwashGrupo de Investigação em Bioquímica e Biologia OralUniversity of Lisbon;Portuguese Institute of Rheumatology;Dentaid SLCompleted18 YearsN/AAll289Phase 4NULL
5NCT01316770
(ClinicalTrials.gov)
May 1, 201115/3/2011Dexamethasone Irrigation of the Parotid Glands in Primary Sjögren's Syndrome SubjectsA Randomized Within-Subject, Double-Blind, Placebo-Controlled Study of Dexamethasone Irrigation of the Parotid Glands in Primary Sjögren's Syndrome SubjectsSjögren's Syndrome;XerostomiaDrug: Dexamethasone Parotid Irrigation;Drug: Placebo Parotid IrrigationNational Institute of Dental and Craniofacial Research (NIDCR)NULLTerminated18 YearsN/AFemale14Phase 2United States
6NCT01647737
(ClinicalTrials.gov)
March 201114/5/2012Green Tea Lozenges for the Management of Dry MouthA Natural Formulation for Patients Diagnosed With XerostomiaXerostomia;Sjogren Syndrome;Dry MouthDietary Supplement: MighTeaFlow;Dietary Supplement: XylitolAugusta UniversityGlaxoSmithKlineCompleted18 Years75 YearsAll60Phase 1/Phase 2United States
7NCT01369589
(ClinicalTrials.gov)
November 20106/6/2011An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal WetnessAn Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness in Subjects With Xerostomia Related to Sjogren's SyndromeXerostomia;Sjogren's SyndromeDrug: P-552;Drug: PlaceboParion SciencesNULLCompleted18 YearsN/AAll24Phase 1/Phase 2United States
8NCT00852839
(ClinicalTrials.gov)
February 200926/2/2009A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's SyndromeA Randomized, Double-Blind, Vehicle-Controlled, Parallel Arm Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's SyndromeDry Mouth Associated With Sjogren's Syndrome;XerostomiaDrug: Placebo;Drug: 552-02Parion SciencesNULLCompleted18 Years80 YearsAll140Phase 2United States
9NCT00637793
(ClinicalTrials.gov)
February 200811/3/2008Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's SyndromeA Double-Blind, Placebo-Controlled, Cross Over Study Using a Latin Square Design to Evaluate the Safety, Tolerability, and Efficacy of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjogren's SyndromeXerostomia;Sjogren's SyndromeDrug: NGX267TorreyPines TherapeuticsNULLCompleted21 Years55 YearsBoth24Phase 2United States
10JPRN-UMIN000000997
2008/01/0128/01/2008The non-blind test crossover controlled trial how we used a physically unimpaired person volunteer about quantity of salivary secretion increase action of gargle remedy of cevimeline hydrochloride hydrate Xerostomia due to Sjogren`s syndromeIt is a gargle with a test drug(Cevimeline hydrochloride hydrate 30mg+Hachiazule(TM)gargle 2g+distilled water 50cc)for two minutes. wash out, It is a gargle with false placebo1 (Cevimeline hydrochloride hydrate 9mg+Hachiazule(TM)gargle 2g+distilled water 50cc)for two minutes. wash out, It is a gargle with false placebo2 (Hachiazule(TM)gargle2g+distilled water 50cc)for two minutes.
It is a gargle with false placebo1 for two minutes. wash out, It is a gargle with false placebo2 for two minutes. wash out, It is a gargle with a test drug for two minutes.
It is a gargle with false placebo2 for two minutes. wash out, It is a gargle with a test drug for two minutes. wash out, It is a gargle with false placebo1 for two minutes.
It is a gargle with a test drug for two minutes. wash out, It is a gargle with false placebo2 for two minutes. wash out, It is a gargle with false placebo1 for two minutes.
It is a gargle with false placebo1 for two minutes. wash out, It is a gargle with a test drug for two minutes. wash out,It is a gargle with false placebo2 for two minutes.
It is a gargle with false placebo2 for two minutes. wash out, It is a gargle with false placebo1 for two minutes. wash out, It is a gargle with a test drug for two minutes.
Department of Dentistry and Oral Surgery, Tochigi National HospitalNational Institute of Public HealthComplete: follow-up complete20years-old90years-oldMale and Female12Phase 1Japan
11NCT00426543
(ClinicalTrials.gov)
January 200723/1/2007Effect of B-cell Depletion in Patients With Primary Sjögren's SyndromePhase 1 Study of B-cell Depletion With Rituximab on Oral, Ocular and General Disease Manifestations in Patients With Primary Sjögren's SyndromePrimary Sjögren's Syndrome;Xerostomia;Hyposalivation;Keratoconjunctivitis Sicca;FatigueDrug: MabThera (rituximab);Drug: Rituximab, MabtheraUniversity of CopenhagenRigshospitalet, DenmarkCompleted18 Years70 YearsFemale21Phase 2Denmark
12NCT00438048
(ClinicalTrials.gov)
November 200620/2/2007A Comparison of Orally Pilocarpine and Artificial Saliva in Xerostomy TreatmentXerostomy Treatment in Patients With Sjogren's Syndrome in Chile :A Double Blind Control Trial Comparing Orally Pilocarpine Drops and Artificial SalivaPrimary Sjogren;Secondary Sjogren;XerostomiaProcedure: pilocarpine;Drug: Artificial SalivaPontificia Universidad Catolica de ChileFormulario MAgistral Farmacias AhumadaCompleted18 YearsN/ABoth76Phase 4Chile
13NCT00233363
(ClinicalTrials.gov)
March 20054/10/2005Exploratory Study for Dry Mouth in Patients With Sjögren’s SyndromeAn Exploratory Study of Rebamipide to Evaluate Efficacy and Safety in the Treatment of Dry Mouth in Patients With Sjögren’s SyndromeXerostomia;Sjogren's SyndromeDrug: RebamipideOtsuka Pharmaceutical Co., Ltd.NULLCompleted20 YearsN/ABoth100Phase 2Japan
14NCT00873496
(ClinicalTrials.gov)
January 200531/3/2009Effects of Hydroxychloroquine on Oral Complaints of Sjögren PatientsEffects of Hydroxychloroquine on Oral Complaints of Sjögren Patients: a Prospective Sample Study.Sjögren's Syndrome;XerostomiaDrug: HydroxychloroquineEge UniversityNULLCompletedN/AN/AFemale30N/ATurkey
15NCT00001599
(ClinicalTrials.gov)
May 19973/11/1999Pilot Study of Thalidomide to Treat Sjogren's SyndromePilot Study of Thalidomide for Sjogren's SyndromeSjogren's Syndrome;XerostomiaDrug: ThalidomideNational Institute of Dental and Craniofacial Research (NIDCR)NULLCompletedN/AN/AFemale28Phase 2United States
16NCT00001598
(ClinicalTrials.gov)
May 19973/11/1999DHEA Treatment for Sjogren's SyndromeDehydroepiandrosterone (DHEA) Treatment for Sjogren's SyndromeLacrimal Apparatus Disease;Salivary Gland Disease;Sjogren's Syndrome;XerostomiaDrug: DehydroepiandrosteroneNational Institute of Dental and Craniofacial Research (NIDCR)NULLCompletedN/AN/AFemale28Phase 2United States